Napo Pharmaceuticals initiates phase III trial of Mytesi for prophylaxis of diarrhea in adult cancer patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Napo Pharmaceuticals Inc., a wholly owned subsidiary of Jaguar Health Inc., has initiated its pivotal phase III clinical trial of crofelemer (Mytesi) for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login